<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04340687</url>
  </required_header>
  <id_info>
    <org_study_id>20191115-2</org_study_id>
    <nct_id>NCT04340687</nct_id>
  </id_info>
  <brief_title>Combination of Rectal Indomethacin and Pancreatic Duct Stenting Versus Indomethacin Alone in Preventing PEP</brief_title>
  <official_title>Combination of Rectal Indomethacin and Pancreatic Duct Stenting Versus Indomethacin Alone in Preventing Post-ERCP Pancreatitis in Patients With Difficult Cannulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rectal indomethacin and pancreatic duct (PD) stenting (PDS) are recommended for the
      prevention of post-ERCP pancreatitis (PEP). However, the effects of the combination of the
      two methods on preventing PEP are controversial. We hypothesized that some group of patients
      with difficult cannulation might benefit from the combination of indomethacin plus PDS (IP)
      compared with indomethacin alone (IN).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall PEP</measure>
    <time_frame>30 days</time_frame>
    <description>PEP was diagnosed if there was a worsening or new onset of pain in the upper abdomen, an elevation in serum amylase of at least three times of the upper limit of the normal range 24h after the procedure and requiring at least two nights of hospitalization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall ERCP related complication</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">664</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IP group</arm_group_label>
    <description>All patients recevied pancreatic duct stent during ERCP and one single dose of 100mg rectal indomethacin after ERCP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IN group</arm_group_label>
    <description>All patients received one single dose of 100mg rectal indomethacin after ERCP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pancreatic duct stenting</intervention_name>
    <description>A stent placed in the pancreatic duct to reduce PEP possibly by relieving pancreatic ductal hypertension that develops because of transient procedure-induced edema and stenosis of the pancreatic orifice</description>
    <arm_group_label>IP group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who underwent ERCP and received administration of rectal indomethacin.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients underwent diagnostic or therapeutic ERCP

          2. With native papilla

          3. With difficult cannulation (cannulation time &gt;10min or cannulation attempts &gt;5 times
             or inadvertently PD cannulation â‰¥1)

          4. Receiving post-ERCP rectal indomethacin

        Exclusion Criteria:

          1. Patients with indications of PD cannulation

          2. No attempt of cannulation due to inaccessible papilla

          3. Non-difficult cannulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xijing Hospital of Digestive Diseases</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Dumonceau JM, Andriulli A, Elmunzer BJ, Mariani A, Meister T, Deviere J, Marek T, Baron TH, Hassan C, Testoni PA, Kapral C; European Society of Gastrointestinal Endoscopy. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014. Endoscopy. 2014 Sep;46(9):799-815. doi: 10.1055/s-0034-1377875. Epub 2014 Aug 22.</citation>
    <PMID>25148137</PMID>
  </reference>
  <reference>
    <citation>Akbar A, Abu Dayyeh BK, Baron TH, Wang Z, Altayar O, Murad MH. Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis. Clin Gastroenterol Hepatol. 2013 Jul;11(7):778-83. doi: 10.1016/j.cgh.2012.12.043. Epub 2013 Jan 30. Review.</citation>
    <PMID>23376320</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Yanglin Pan</investigator_full_name>
    <investigator_title>Associated professor</investigator_title>
  </responsible_party>
  <keyword>Indomethacin</keyword>
  <keyword>Double-guidewire technique</keyword>
  <keyword>Adverse events</keyword>
  <keyword>PEP</keyword>
  <keyword>PD stenting</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

